Oculis (NASDAQ:OCS) Shares Up 7% – What’s Next?

Oculis Holding AG (NASDAQ:OCS)’s stock price shot up 7% during mid-day trading on Thursday . The stock traded as high as $30.25 and last traded at $29.8670. 372,065 shares traded hands during mid-day trading, an increase of 6% from the average session volume of 349,370 shares. The stock had previously closed at $27.91.

Analysts Set New Price Targets

Several brokerages have issued reports on OCS. HC Wainwright raised their price objective on shares of Oculis from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. JPMorgan Chase & Co. raised their price objective on shares of Oculis from $38.00 to $42.00 and gave the stock an “overweight” rating in a research report on Monday. Guggenheim began coverage on shares of Oculis in a research report on Wednesday. They set a “buy” rating and a $75.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Finally, Wall Street Zen downgraded shares of Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $49.38.

Oculis Price Performance

The company’s 50-day simple moving average is $27.39 and its 200-day simple moving average is $24.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -14.49 and a beta of 0.38.

Oculis (NASDAQ:OCS) last announced its earnings results on Monday, May 11th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%.The business had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.25 million. Research analysts forecast that Oculis Holding AG will post -2.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in OCS. Gildi lifeyrissjodur bought a new position in shares of Oculis during the fourth quarter worth approximately $50,250,000. Perceptive Advisors LLC bought a new position in shares of Oculis during the fourth quarter worth approximately $9,862,000. Aberdeen Group plc increased its holdings in shares of Oculis by 39.4% during the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after purchasing an additional 493,827 shares during the period. SR One Capital Management LP increased its holdings in shares of Oculis by 98.8% during the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after purchasing an additional 318,522 shares during the period. Finally, Alyeska Investment Group L.P. increased its holdings in shares of Oculis by 152.3% during the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after purchasing an additional 200,000 shares during the period. 22.30% of the stock is owned by institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.